Dr. Cohen provides regular melanoma-related commentary to various media, including CTV, Global and CBC news outlets.
MISSISSAUGA, ON — January 25, 2024 – MedX Health Corp. (“MedX” or the “Company”) (TSX VENTURE: MDX) is pleased to announce that it has appointed Dr. Paul Cohen, a board-certified dermatologist and Fellow of the Royal College of Physicians and Surgeons of Canada, as Medical Spokesperson. Dr. Cohen is also a diplomat of the American Board of Dermatology and is a member of numerous associations, including the Canadian Dermatological Association and the Toronto Dermatological Society. He was awarded the Ben Fisher Galderma fellowship in clinical dermatology, where he completed additional training in cosmetic, surgical and pediatric dermatology.
“Dr. Cohen is a highly respected physician renowned across North America for his exceptional work as a dermatologist focused on melanoma awareness. He is a leader in the field of dermatological medicine, and we are honoured to have him as our medical spokesperson,” said Michael Druhan, President of Dermatology Services. “Paul was an early adopter of our teledermatology screening platform, and he has seen first-hand the positive impact our technology has on people’s lives. Having Dr. Cohen as our medical spokesperson is meaningful, and we believe his insights will help MedX increase awareness of the importance of early screening of suspicious moles and lesions, especially for the at-risk population,” Mr. Druhan added.
“The value of MedX’s innovative technology that helps save lives is undeniable. Skin cancer rates are rising expeditiously around the world, and in some areas of the globe, it’s bordering on epidemic levels. Having access to MedX’s teledermatology platform for the at-risk population would be a game-changer and would save countless lives globally,” Dr. Cohen said.
Dr. Cohen has been using MedX’s SIAscopy screening technology in his practice at Rosedale Dermatology Centre and has also provided patient skin assessments for a number of MedX’s pilot projects. “MedX’s teledermatology platform allows me to confidently assess patients, and it fits perfectly in my workflow, which allows me to see more patients without compromising quality care,” Dr. Cohen noted.
About MedX Health Corp.:
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. Visit www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.